Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

References

• WildSRoglicGGreenASicreeRKingHGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042751047105315111519
   PubMed Web of Science ®Google Scholar
• DCCT/EDIC: Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitusJAMA2002287192563256912020338
   PubMed Web of Science ®Google Scholar
• BjarnegårdNArnqvistHJLindströmTJonassonLJönssonALänneTLong-term hyperglycemia impairs vascular smooth muscle cell function in women with type 1 diabetes mellitusDiab Vasc Dis Res200961253119156625
   PubMed Web of Science ®Google Scholar
• PotenzaMAGagliardiSNacciCCarratu’MRMontagnaniMEndothelial dysfunction in diabetes: from mechanisms to therapeutic targetsCurr Med Chem20091619411219149564
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationEconomic costs of diabetes in the US in 2007Diabetes Care200831359661518308683
   PubMed Web of Science ®Google Scholar
• HolmesJMcGillSKindPBottomleyJGillamSMurphyMHealth-related quality of life in type 2 diabetes (TARDIS-2)Value Health20003Suppl 1475116464209
   PubMedGoogle Scholar
• ValensiPBenroubiMBorziVIMPROVE Study Group Expert PanelThe IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohortsInt J Clin Pract200862111809181918811598
   PubMed Web of Science ®Google Scholar
• VinikAAdvancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapyClin Ther200729Spec No12361253
   Web of Science ®Google Scholar
• IDF Clinical Guidelines Task ForceGlobal guideline for Type 2 diabetesBrusselsInternational Diabetes Federation2005 http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf
   Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000321725840541210938048
   PubMed Web of Science ®Google Scholar
• AtkinsonMAEisenbarthGSType 1 diabetes: new perspectives on disease pathogenesis and treatmentLancet2001 Jul 213589277:22122911476858
   PubMed Web of Science ®Google Scholar
• JeitlerKHorvathKBergholdAContinuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysisDiabetologia200851694195118351320
   PubMed Web of Science ®Google Scholar
• SchiaffiniRPateraPIBizzarriCCiampaliniPCappaMBasal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulinJ Endocrinol Invest200730757257717848840
   PubMed Web of Science ®Google Scholar
• RenardEIntensive insulin therapy today: ‘basal-bolus’ using multiple daily injections or CSII?Diabetes Metab2005314 Pt 24S404S44
   Web of Science ®Google Scholar
• HarrisMIEpidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM)Clin Invest Med19951842312398549007
   PubMed Web of Science ®Google Scholar
• GerichJEThe genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivityEndocr Rev1998194915039715377
   PubMed Web of Science ®Google Scholar
• MasonCCHansonRLKnowlerWCProgression to type 2 diabetes characterized by moderate then rapid glucose increasesDiabetes2007562054206117473220
   PubMed Web of Science ®Google Scholar
• LebovitzHEInsulin secretagogues: old and newDiabetes Reviews19997139153
   Google Scholar
• U.K. Prospective Diabetes Study GroupUK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive diseaseDiabetes19954411124912587589820
   PubMed Web of Science ®Google Scholar
• SteynNPLambertEVTabanaHNutrition interventions for the prevention of type 2 diabetesProc Nutr Soc2009681557019068148
   PubMed Web of Science ®Google Scholar
• TurnerRCCullCAFrighiVHolmanRRGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) GroupJAMA1999281212005201210359389
   PubMed Web of Science ®Google Scholar
• WrightABurdenACFPaiseyRBfor the UK Prospective Diabetes Study GroupSulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57)Diabetes Care20022533033611815505
   PubMed Web of Science ®Google Scholar
• GarberAJLigthelmRChristiansenJSLieblAPremixed insulin treatment for type 2 diabetes: analogue or human?Diabetes Obes Metab20079563063917697056
   PubMed Web of Science ®Google Scholar
• BrangeJVolundAInsulin analogs with improved pharmacokinetic profilesAdvanced Drug Delivery Reviews19993530733510837704
   PubMed Web of Science ®Google Scholar
• BolliGBPhysiological insulin replacement in type 1 diabetes mellitusExp Clin Endocrinol Diabetes2001109Suppl 2S317S33211460580
   PubMed Web of Science ®Google Scholar
• WeyerCHeiseTHeinemannLInsulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixtureDiabetes Care19972010161216149314644
   PubMed Web of Science ®Google Scholar
• JacobsenLVSogaardBRiisAPharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspartEur J Clin Pharmacol20005639940311009049
   PubMed Web of Science ®Google Scholar
• McSorleyPTBellPMJacobsenLVKristensenALindholmATwice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitusClin Ther200224453053912017398
   PubMed Web of Science ®Google Scholar
• HermansenKColomboMStorgaardHØStergaardAKølendorfKMadsbadSImproved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetesDiabetes Care200225588388811978685
   PubMed Web of Science ®Google Scholar
• LuzioSDunseathGPeterRPauvadayVOwensDRComparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetesDiabetologia20064961163116816596358
   PubMed Web of Science ®Google Scholar
• MortensenHKocovaMTengLYKeidingJBrucknerIPhilotheouABiphasic insulin aspart vs human insulin in adolescents with type 1 diabetes on multiple daily insulin injectionsPediatr Diabetes20067141016489968
   PubMed Web of Science ®Google Scholar
• ChenJWLauritzenTBojesenAChristiansenJSMultiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetesDiabetes Obes Metab20068668268917026493
   PubMed Web of Science ®Google Scholar
• HermansenKVaalerSMadsbadSPostprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetesMetabolism200251789690012077738
   PubMed Web of Science ®Google Scholar
• BoehmBOHomePDBehrendCKampNMLindholmAPremixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patientsDiabet Med200219539339912027927
   PubMed Web of Science ®Google Scholar
• RaskinPAllenEHollanderPINITIATE Study GroupInitiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogsDiabetes Care200528226026515677776
   PubMed Web of Science ®Google Scholar
• RaskinPRHollanderPALewinAGabbayRABodeBGarberAJon behalf of the INITIATE Study GroupBasal insulin or premix analogue therapy in type 2 diabetes patientsEur J Intern Med2007181566217223044
   PubMed Web of Science ®Google Scholar
• RaskinPMatfinGSchwartzSLAddition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)Diabetes Obes Metab2009111273217941873
   PubMed Web of Science ®Google Scholar
• KannPHWascherTZackovaVStarting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepirideExp Clin Endocrinol Diabetes2006114952753217115351
   PubMed Web of Science ®Google Scholar
• Velojic-GolubovicMMikicDPesicMDimicDRadenkovicSAnticSBiphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetesJ Endocrinol Invest2009321232719337010
   PubMed Web of Science ®Google Scholar
• KiloCMezitisNJainRMerseyJMcGillJRaskinPStarting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metforminJ Diabetes Complications200317630731314583174
   PubMed Web of Science ®Google Scholar
• KabadiUMKabadiMComparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetesDiabetes Res Clin Pract200672326527016406190
   PubMed Web of Science ®Google Scholar
• BebakarWMChowCCKadirKASuwanwalaikornSVazJABechOMBIAsp-3021 study groupAdding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetesDiabetes Obes Metab20079572473217593237
   PubMed Web of Science ®Google Scholar
• HomePDBaileyCJDonaldsonJChenHStewartMWA double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetesDiabet Med200724661862517403121
   PubMed Web of Science ®Google Scholar
• LieblAPragerRBinzKKaiserMBergenstalRGallwitzBPREFER Study GroupComparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trialDiabetes Obes Metab2009111455218643839
   PubMed Web of Science ®Google Scholar
• UshakovaOSokolovskayaVMorozovaAComparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in RussiaClin Ther200729112374238418158078
   PubMed Web of Science ®Google Scholar
• KvapilMSwatkoAHilbergCShestakovaMBiphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetesDiabetes Obes Metab200681394816367881
   PubMed Web of Science ®Google Scholar
• YangWJiQZhuDBiphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugsDiabetes Care200831585285618268073
   PubMed Web of Science ®Google Scholar
• RazIStranksSFilipczakREfficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label studyClin Ther20052791432144316291416
   PubMed Web of Science ®Google Scholar
• BoehmBOVazJABrøndstedLHomePDLong-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetesEur J Intern Med200415849650215668084
   PubMedGoogle Scholar
• GarberAJWahlenJWahlTAttainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study)Diabetes Obes Metab200681586616367883
   PubMed Web of Science ®Google Scholar
• McNallyPGDeanJDMorrisADWilkinsonPDCompionGHellerSRUsing continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetesDiabetes Care20073051044104817277042
   PubMed Web of Science ®Google Scholar
• BarnettAHSummarising the use of thiazolidinediones with insulinBr J Diab Vasc Dis200777580
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes–2009Diabetes Care200932Suppl 1S13S6119118286
   PubMed Web of Science ®Google Scholar
• KorytkowskiMBellDJacobsenCSuwannasariRFlexPen Study TeamA multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitusClin Ther200325112836284814693308
   PubMed Web of Science ®Google Scholar
• KorytkowskiMNiskanenLAsakuraTFlexPen: addressing issues of confidence and convenience in insulin deliveryClin Ther200527Suppl BS89S10016519040
   PubMed Web of Science ®Google Scholar
• BruntonSInitiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pensDiabetes Technol Ther200810424725618715198
   PubMed Web of Science ®Google Scholar
• LindholmAJensenLBHomePDRaskinPBoehmBORåstamJImmune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetesDiabetes Care200225587688211978684
   PubMed Web of Science ®Google Scholar
• ChenJWFrystykJLauritzenTChristiansenJSImpact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetesEur J Endocrinol2005153690791316322398
   PubMed Web of Science ®Google Scholar
• BreumLAlmdalTEikenPLundPChristiansenEon behalf of the Danish BIAsp Study GroupInitiating or Switching to Biphasic Insulin Aspart 30/70 Therapy in Subjects with Type 2 Diabetes Mellitus. An Observational StudyRev Diabet Stud20085315416219099087
   PubMedGoogle Scholar
• ValensiPBenroubiMBorziVon behalf of the IMPROVETM Study Group Expert PanelInitiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30.70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVETM observational studyInt J Clin Pract200963352253119187170
   PubMed Web of Science ®Google Scholar
• ShahSBenroubiMBorziVon behalf of the IMPROVETM Study Group Expert PanelSafety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVETM observational studyInt J Clin Pract200963457458219210701
   PubMed Web of Science ®Google Scholar
• KhutsoaneDSharmaSKAlmustafaMPRESENT Study GroupBiphasic insulin aspart 30 treatment improves glycemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT studyDiabetes Obes Metab200810321222218269636
   PubMed Web of Science ®Google Scholar
• JangHCGulerSShestakovaMPRESENT Study GroupWhen glycemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT studyInt J Clin Pract20086271013101818479365
   PubMed Web of Science ®Google Scholar
• ShestakovaMSharmaSKAlmustafaMTransferring type 2 diabetes patients with uncontrolled glycemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT studyCurr Med Res Opin200723123209321418005503
   PubMed Web of Science ®Google Scholar
• SharmaSKAl-MustafaMOhSJBiphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT studyCurr Med Res Opin200824364565218215338
   PubMed Web of Science ®Google Scholar
• LigthelmRJBorzìVGumprechtJKawamoriRWenyingYValensiPImportance of observational studies in clinical practiceClin Ther200729Spec no12841292
   Web of Science ®Google Scholar
• ShahSØrskovCKawamoriRSwitching to NovoMix® 30 (BIAsp 30) improves glycemic control in patients with type 2 diabetes previously treated with insulin: subgroup analysis from the IMPROVETM studyDiabetes200857Suppl 1A592
   Google Scholar